Certified by Founder
Lodge
Latigo Biotherapeutics, Inc.
start up
United States
- Thousand Oaks, CA
- 15/02/2024
- Series A
- $135,000,000
Latigo Biotherapeutics Inc., headquartered in Thousand Oaks, CA, is a privately held clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target the fundamental mechanism of pain transduction. The company’s proprietary, in-house technology generates novel drugs against targets validated by human genetics using the most advanced artificial intelligence, machine learning, structure-based, and knowledge-based design techniques to optimize potency and selectivity. The company is backed by top-tier investors, including Westlake Village BioPartners, 5AM Ventures, Foresite Capital, and Corner Ventures.
- Industry Biotechnology Research
- Website https://latigobio.com/
- LinkedIn https://www.linkedin.com/company/latigobio/
SkyFi | $12,700,000 | (Jan 15, 2026)
Musical AI | $4,500,000 | (Jan 15, 2026)
Harmattan AI | $200,000,000 | (Jan 15, 2026)
Tive | $20,000,000 | (Jan 15, 2026)
IO River | $20,000,000 | (Jan 15, 2026)
Flip (US) | $20,000,000 | (Jan 15, 2026)
PayMedix | $33,000,000 | (Jan 14, 2026)
bricks.sh | $1,863,303 | (Jan 14, 2026)
Diffraqtion | $4,200,000 | (Jan 14, 2026)
WithCoverage | $42,000,000 | (Jan 14, 2026)
Converge Bio | $25,000,000 | (Jan 14, 2026)